Austin Health

Title
Treatment with Multiple Therapeutic Classes of Medication Is Associated with Survival after Stroke.
Publication Date
2022
Author(s)
Kilkenny, Monique F
Olaiya, Muideen T
Dalli, Lachlan L
Kim, Joosup
Andrew, Nadine E
Sanfilippo, Frank M
Thrift, Amanda G
Nelson, Mark
Pearce, Christopher
Sanders, Lauren
Dewey, Helen
Clissold, Benjamin
Grimley, Rohan
Cadilhac, Dominique A
Subject
Adherence
Medication
Population register
Secondary prevention
Stroke
Type of document
Journal Article
OrcId
0000-0002-3375-287X
0000-0002-4079-0428
0000-0001-8162-682X
DOI
10.1159/000520823
Abstract
Treatment with several therapeutic classes of medication is recommended for secondary prevention of stroke. We analyzed the associations between the number of classes of prevention medications supplied within 90 days after discharge for ischemic stroke (IS)/transient ischemic attack (TIA) and survival. This is a retrospective cohort study of adults with first-ever IS/TIA (2010-2014) from the Australian Stroke Clinical Registry individually linked with data from national pharmaceutical and Medicare claims. Exposure was the number of classes of recommended medications, i.e., blood pressure-lowering, antithrombotic, or lipid-lowering agents, supplied to patients within 90 days after discharge for IS/TIA. The longitudinal association between the number of classes of medications and survival was evaluated with Cox proportional hazards regression models using the landmark approach. A landmark date of 90 days after hospital discharge was used to separate exposure and outcome periods, and only patients who survived until this date were included. Of 8,429 patients (43% female, median age 74 years, 80% IS), 607 (7%) died in the year following 90 days after discharge. Overall, 56% of patients were supplied all 3 classes of medications, 28% 2 classes of medications, 11% 1 class of medications, and 5% no class of medications. Compared to patients supplied all 3 medication classes, adjusted hazard ratios for all-cause mortality ranged from 1.43 (95% confidence interval [CI]: 1.18-1.72) in those supplied 2 medication classes to 2.04 (95% CI: 1.44-2.88) in those supplied with no medication class. Treatment with all 3 classes of guideline-recommended medications within 90 days after discharge was associated with better survival. Ongoing efforts are required to ensure optimal pharmacological intervention for secondary prevention of stroke.
Link
Citation
Neuroepidemiology 2022; 56(1): 66-74
Jornal Title
Neuroepidemiology

Files:

NameSizeformatDescriptionLink